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We report a case of Buruli ulcer in a tourist from the 
United Kingdom. The disease was almost certainly acquired 
in Brazil, where only 1 case had previously been reported. 
The delay in diagnosis highlights the need for physicians to 
be aware of the disease and its epidemiology.
B
uruli ulcer (BU) is caused by infection with Myco-
bacterium ulcerans and can lead to extensive destruc-
tion of skin and soft tissue (1). The disease is endemic in 
>30 tropical and subtropical countries worldwide (2,3). 
It is associated with exposure to stagnant water or slow-
ﬂ  owing rivers. Most cases occur in Africa, and only 1 
case has been previously reported from Brazil (4). It has 
rarely been described in travelers returning from an en-
demic area (5,6). We report a case of a UK tourist with M. 
ulcerans infection after a trip to Brazil and other parts of 
Latin America.
The Case
The travel itinerary for this 27-year-old man, his his-
tory of water exposure, and the clinical progression of the 
lesion all support the hypothesis that he acquired the infec-
tion in the Pantanal region of southern Brazil. He spent 4 
days there starting on August 11, 2007, and participated in 
trekking on horseback through wetlands and a canoe trip 
during which he was immersed in water on several occa-
sions. From that region, he ﬂ  ew to the Bolivian cities of 
Santa Cruz and La Paz, before traveling overland to Lake 
Titicaca. After 3 days there, he journeyed on to Arequipa, 
Peru. On September 2, he took a bus trip to the Colca Can-
yon. During this journey, 17 days after leaving the Pantanal, 
he ﬁ  rst noticed a small, painless papule with an overlying 
scab on the lateral aspect of his left knee. He had no history 
of trauma or insect bite and no further water exposure after 
leaving Brazil.
He then visited Cuzco and some surrounding sites for 
a week, before entering the rainforests of Manu National 
Park for a 3-day visit on September 14. Here his leg was 
immersed in stagnant water on several occasions, although 
the papular lesion was well established and enlarging by 
this time. From Cuzco, he went to Lima, the capital of Peru, 
where he arrived on September 27. When examined in a lo-
cal clinic 1 week later, the lesion was described as a 1-cm, 
painless ulcer. Over the next 6 weeks, it gradually increased 
in size during his travels through Ecuador.
He returned to the UK on November, 15, 2007, and 
attended the dermatology department of his local hospital. 
The ulcer was debrided with larval therapy and measured 11 
× 6 cm (Figure 1, panel A). A skin biopsy was performed, 
and multiple acid-fast bacilli (AFB) were seen on micros-
copy. Histologic analysis showed necrosis of the subcuta-
neous fat and deep dermal tissue with clusters of AFB but 
no granuloma formation (Figure 2). Tissue samples were 
also sent for mycobacterial culture, but results were nega-
tive after 12 weeks incubation. The patient was treated with 
clarithromycin for presumed M. marinum infection.
Despite this therapy, the ulcer continued to enlarge, 
reaching 16 × 10 cm with deeply undermined edges and 
necrosis of the surrounding skin (Figure 1, panel B). In 
January 2008, he was referred to the Infection and Travel 
Medicine Department at our hospital in Leeds. BU was 
suspected clinically. A swab taken from beneath the ulcer 
edge was positive for AFB on direct microscopy. A sample 
was sent to the Institute of Tropical Medicine in Antwerp, 
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Figure 1. Progression of Buruli ulcer adjacent to the left knee of 
United Kingdom tourist after returning from Latin America. A) 
November 2007, on patient’s return to the United Kingdom; B) 
January 2008, before Mycobacterium ulcerans therapy; C) April 
2008, after 12 weeks of antimicrobial drug therapy; D) January 
2009, 9 months after split-skin grafting.Belgium for PCR testing for M. ulcerans by detection of 
the insertion sequence 2404 (IS2404), which was positive. 
Further prolonged cultures for AFB were negative in both 
the United Kingdom and Belgium.
Because of the extensive nature of the ulcer, the pa-
tient was treated for 12 weeks with a daily regimen of 600 
mg of oral rifampicin and 400 mg of moxiﬂ  oxacin. Intra-
venous amikacin, 15 mg/kg once a day, was added during 
the ﬁ  rst 8 weeks. Response to antimicrobial treatment was 
satisfactory: the ulcer reduced to 12 × 10 cm, the edges 
were no longer undermined, and the surrounding skin ap-
peared healthy (Figure 1, panel C). To accelerate healing, 
split skin grafting was performed 1 month after comple-
tion of antimicrobial drug therapy. Nine months later, 
complete healing had occurred (Figure 1, panel D).
The clinical diagnosis of BU is usually straightforward 
once the disease has been considered. However, diagnosis 
may be delayed, as in this case, when the patient is in a 
country in which BU is not endemic, especially when ex-
posure has occurred in a region where the disease is not 
well recognized. A major diagnostic advance has been the 
development of PCR for insertion sequence 2404, one of 2 
multicopy insertion sequences in the M. ulcerans genome 
(7). The technique, usually performed on tissue biopsy 
samples, can also be performed directly from ulcer swabs 
(8) and has a sensitivity and speciﬁ  city of ≈100% (9). It is 
theoretically a rapid test but is not routinely available in 
many countries, including those where BU is endemic.
Conclusions
Data from the World Health Organization indicate that 
the greatest number of BU cases occur in western Africa 
(2). Cases have been reported from the Western Hemi-
sphere, although apart from French Guiana, the disease 
is considered rare in Central or South America (3). For 
example, in Peru during 1969–2007, only 11 cases were 
documented (10). BU may be endemic in Brazil, but, to our 
knowledge, only 1 case has been previously reported from 
this country (4).
The use of mycobacterial-interspersed repetitive-unit 
variable number of tandem repeat typing (MIRU-VNTR) 
has made it possible to distinguish between different strains 
of M. ulcerans (11). Most countries outside Africa have 
their own unique MIRU-VNTR proﬁ  le(s). The proﬁ  le of 
this patient’s isolate was determined as 10112N, identical 
to that recovered from a patient from Tumbes in northwest 
Peru (10). This previous case could indicate that our patient 
acquired his infection in Peru. The epidemiologic evidence, 
however, supports the hypothesis that it was acquired in 
the Pantanal region of Brazil, suggesting that this MIRU-
VNTR proﬁ   le has a geographic distribution wider than 
originally thought.
Cases of BU diagnosed in countries where the disease 
is not endemic are rare. To our knowledge, only 21 such 
cases have been reported (12). These cases may occur ei-
ther in a migrant from a country endemic for BU, where 
the disease is acquired in the country of origin, or in a trav-
eler from a country where BU is not endemic, as in this 
case. This BU case appears to be only the second reported 
in a traveler returning from the Western Hemisphere (12). 
Physicians should be aware of its features because early 
diagnosis and treatment help prevent long-term disability 
that may result from this infection. Cases such as this one, 
reported from countries where BU is rare, serve as a re-
minder that the disease is probably endemic to a larger area 
than is usually considered.
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Figure 2. Histologic analysis showing necrosis of subcutaneous fat 
and deep dermal tissue of the patient. A) Noninﬂ  ammatory infarction-
like necrosis related to cytopathic effect of the mycolactone toxin 
secreted by Mycobacterium ulcerans. B) Abundant mycobacteria 
within the necrosis.Buruli Ulcer in UK Tourist
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